On the physiological disposition and possible mechanism of the antihypertensive action of debrisoquin.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001711:Biotransformation; D001794:Blood Pressure / Q000187:drug effects; D001798:Blood Proteins / Q000378:metabolism; D001949:Bretylium Compounds / Q000494:pharmacology; D002339:Carotid Arteries / Q000187:drug effects; D005260:Female; D007422:Intestines / Q000032:analysis; D007546:Isoquinolines / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology* / Q000502:physiology / Q000652:urine; D008099:Liver / Q000032:analysis; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009206:Myocardium / Q000032:analysis / Q000166:cytology / Q000378:metabolism; D010830:Physostigmine / Q000494:pharmacology; D011485:Protein Binding; D051381:Rats; D013565:Sympatholytics / Q000494:pharmacology
D000959:Antihypertensive Agents; D001798:Blood Proteins; D001949:Bretylium Compounds; D007546:Isoquinolines; D008996:Monoamine Oxidase Inhibitors; D013565:Sympatholytics; D010830:Physostigmine